研究業績(原著と症例報告のみ) 2015年

原著論文
1.
Incidence, serum IgE and TARC/CCL17 levels of atopic dermatitis in association with other related allergic diseases: An update from the Ishigaki Island cohort. Takeuchi S, Esaki H, Furusyo N, Hayashida S, Yamamura K, Tsuji G, Takemura M, Hayashi J, Furue M. Acta Dermato Venereologica 95: 480-484, 2015
2.
Bacterial infection as an adverse fffect of telaprevir-based triple therapy for chronic hepatitis C infection. Kawano A, Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Dohmen K, Nomura H, Takahashi K, Satoh T, Azuma K, Tanabe Y, Shimoda S, Kotoh K, Hayashi J, The Kyushu University Liver Disease Study (KULDS) Group. Internal Medicine 54: 567-572, 2015
3.
The association between objective tongue color and endoscopic findings:results from the Kyushu and Okinawa population study (KOPS) Kainuma M, Furusyo N, Urita Y, Nagata M, Ihara T, Oji T, Nakaguchi T, Namiki T, Hayashi J. BMC Complement Altem Med 15: 327, 2015
4.
Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J. Antivir Ther 20: 185-92, 2015.
5.
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. J Gastroenterol Hepatol 30: 1309-16, 2015.
6.
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. J Viral Hepat 22: 992-1001, 2015.
7.
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. J Gastroenterol Hepatol 30: 1759-67, 2015.
8.
Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. Shimizu M, Hoshide S, Ishikawa J, Yano Y, Eguchi K, Kario K. Am J Hypertens. 28: 980-986, 2015.
9.
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. Shimizu M, Furusyo N, Ikezaki H, Ogawa E, Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M, Hayashi J. World J Gastroenterol. 21: 2116-2123, 2015.
10.
Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS). Shimizu M, Furusyo N, Mitsumoto F, Takayama K, Ura K, Hiramine S, Ikezaki H, Ihara T, Mukae H, Ogawa E, Toyoda K, Kainuma M, Murata M, Hayashi J. Atherosclerosis. 238: 207-212, 2015.
11.
Blood Pressure Self-Measured at Home as a Novel Determinant of Organ Damage: Japan Morning Surge Home Blood Pressure (J-HOP) Study. Kario K, Hoshide S, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, Yano Y, Eguchi K, Matsui Y, Shimizu M, Ishikawa J, Ishikawa S; J-HOP study group. Sleep J Clin Hypertens (Greenwich). 17: 340-348, 2015.
12.
Glycated Albumin as a diagnostic tool for diabetes in a general Japanese population Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ura K, Hiramine S, Mitsumoto F, Takayama K, Murata M, Kohzuma T, Ai M, Schaefer EJ, Hayashi J Metabolism ? Clinical and Experimental 64: 698-705, 2015
13.
The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients. Mitsumoto F, Murata M, Ura K, Takayama K, Hiramine S, Shimizu M, Toyoda K, Ogawa E, Furusyo N, Hayashi J. J Infect Chemother 21: 264-71, 2015.
14.
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. World J Gastroenterol 21: 4696-4706, 2015.
15.
A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H, Watanabe H, Ueno Y, Korenaga M, Murata K, Masaki N, Hayashi J, Thomas DL, Mizokami M. J Gastroenterol. 50: 1069-77, 2015.
16.
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J World J Hepatol. 7: 2688-95, 2015.


症例報告
1.
経大腸内視鏡的バンコマイシン投与にて救命し得た重症偽膜性腸炎の1例 武田倫子、古賀恒久、石丸敏之、澤山泰典 感染症誌 89: 406-409, 2015.
2.
肺小細胞癌に併発した低ナトリウム血症に五苓散が有効であった1例 坂本篤彦、栗山一道、木下義晃、日高孝子、貝沼茂三郎 日東医誌 66: 124-130, 2015

研究分野・研究実績トップへ戻る